Published • loading... • Updated
FDA Expands Tzield Use for Children With Type 1 Diabetes
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Expands Tzield Use for Children With Type 1 Diabetes
WASHINGTON, D.C. — The U.S. Food and Drug Administration has expanded the approved use of Tzield (teplizumab) to children ages 8 to 17 who have been recently diagnosed with Stage 3 type 1 diabetes, marking the first approved therapy aimed at delaying the decline of insulin production after diagnosis. The accelerated approval, granted June 12, broadens the drug’s role in type 1 diabetes treatment and could provide pediatric patients with addition…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
